Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,280.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00. Following the transaction, the president now owns 2,839,260 shares of the company’s stock, valued at approximately $28,790,096.40. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total value of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.

Gyre Therapeutics Trading Up 9.9 %

NASDAQ:GYRE traded up $1.02 during mid-day trading on Tuesday, reaching $11.35. The stock had a trading volume of 154,618 shares, compared to its average volume of 73,193. The business’s 50 day moving average is $11.26 and its 200 day moving average is $12.34. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $19.96.

Analyst Ratings Changes

Separately, Noble Financial started coverage on Gyre Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds have recently bought and sold shares of GYRE. Geode Capital Management LLC boosted its holdings in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after buying an additional 43,840 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock worth $1,386,000 after acquiring an additional 918 shares during the period. State Street Corp grew its holdings in shares of Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock worth $1,251,000 after purchasing an additional 8,624 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Gyre Therapeutics in the fourth quarter valued at $1,225,000. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.